Robert Huddart
Papers
2
Total Citations
12
H-Index
2
About
Dr. Robert Huddart is a leading urologic oncologist whose research focuses on improving treatment for testicular cancer, particularly seminoma. His major contributions center on reducing treatment toxicity while maintaining excellent outcomes. Dr. Huddart pioneered the use of minimally invasive retroperitoneal lymph node dissection (MI-RPLND) combined with single-dose carboplatin as an alternative to standard multi-agent chemotherapy or radiotherapy for clinical stage IIa seminoma. This approach, detailed in his most-cited 2019 work (10 citations), aims to spare patients from the long-term toxicities of cisplatin-based regimens. His 2020 follow-up study (2 citations) further validates these outcomes, demonstrating that this combined modality can achieve effective disease control with less intensive therapy. Dr. Huddart’s work represents a paradigm shift in seminoma management, offering a less toxic yet equally effective treatment pathway. His research is highly impactful for clinicians seeking to personalize care and reduce overtreatment, making him a key figure in the evolution of testicular cancer therapy.
Research Focus
Key Achievements
Top Papers
- 1
- 2